Pfizer: Meningitis, Meningococcal trials

The registry lists 10 Meningitis, Meningococcal studies with Pfizer as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 3Phase 2 5Phase 3 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of AgeCompletedNCT01768117Phase 2Results posted
• A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 YearsCompletedNCT01352793Phase 3Results posted
• Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy AdultsCompletedNCT00879814Phase 1Results posted
• A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In AdolescentsCompletedNCT00808028Phase 2Results posted
• Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy InfantsTerminatedNCT00798304Phase 2Results posted
• Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In AdultsCompletedNCT00780806Phase 1/2
• Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in InfantsCompletedNCT00314041Phase 2
• Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy AdultsCompletedNCT00297687Phase 1
• Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216CompletedNCT00161941
• Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy InfantsCompletedNCT00161928Phase 3